Skip to content
Open access

Evidence for a tubular basement membrane–cilia connection in autosomal dominant polycystic kidney disease pathogenesis

Sep 2026 · Journal of Clinical Investigation · Vol 136 · 0 citations · 25 references
Medicine

TL;DR

Using in vivo, ex vivo, tubule-on-chip, and cellular models of ADPKD, Mazloum and colleagues connect cilia-dependent tubule dilation and TBM thinning to early-stage cystogenesis and identify a cilia-dependent TBM remodeling expression signature in affected tubules.

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), mainly driven by pathogenic variants in PKD1 and PKD2, is the most common inherited cause of kidney failure. Details of ADPKD pathogenesis are incompletely resolved, but primary cilia are an integral component. There is also evidence for changes to the tubular basement membrane (TBM) in early disease. In this issue of the JCI, Mazloum and colleagues link cilia-dependent, PKD1-mediated regulation of the TBM to ADPKD pathogenesis. Using in vivo, ex vivo, tubule-on-chip, and cellular models of ADPKD, they connect cilia-dependent tubule dilation and TBM thinning to early-stage cystogenesis. Moreover, they identify a cilia-dependent TBM remodeling expression signature in affected tubules and suggest that PC1 loss compromises TBM stiffness. By integrating roles for cilia at the apical membrane and extracellular matrix at the basolateral membrane in cystogenesis, this work highlights the TBM as an additional area for investigation of therapeutic and biomarker discovery in ADPKD.

Read PDF

Similar papers

Open access Sep 2026

Loss of ADAMTS9 disrupts ciliogenesis and collagen homeostasis resulting in Nephronophthisis-like polycystic kidneys.

ADAMTS9 mutations cause the ciliopathies nephronophthisis and Joubert syndrome. Here we demonstrated that deletion of ADAMTS9 in the proximal nephron led to polycystic kidney development in mice. In males, Adamts9 deletion caused kidneys to become highly cystic while remaining small without undergoing enlargement. In c...

Sydney Fischer, Karyn L. Robert, Manu Ahmed et al. · 0 citations
Sep 2026

CFTR correctors suppress Ca²⁺-cAMP signaling and cyst growth in primary cultures of ARPKD cholangiocytes.

Autosomal recessive polycystic kidney disease (ARPKD) is a severe ciliopathy caused by mutations in Polycystic kidney and hepatic disease 1 gene (PKHD1), resulting in progressive renal and hepatobiliary disease for which effective targeted therapies are lacking. Although reduced cystic fibrosis transmembrane conductanc...

Abhishek Sharma, M. Afshani, Tanvi Sharma et al. · 0 citations
Open access Aug 2026

Targeting Runx1 Slows Cyst Growth in Autosomal Dominant Polycystic Kidney Disease

Mechanistically, Runx1 enhances proliferation of cyst‐lining epithelial cells by activating the AKT–mTOR, MAPK, and STAT3 signaling cascades, while suppressing p53‐mediated apoptosis.

Yue-Yue Zhang, Chang Liu, Jun-Chi Liu et al. · 0 citations
Aug 2026

Ciliary ARL13B Drives Cystogenesis in the Kidney via Its GEF Activity.

BACKGROUND Polycystic kidney disease (PKD) is the leading genetic cause of kidney failure, resulting in the accumulation of fluid filled cysts and gross enlargement of the kidney. Mutations in PKD1 or PKD2, which encode ciliary polycystin proteins, are the most common cause of PKD. These proteins function in a cilia-de...

R. V. Van Sciver, Avery Forster, Leslie Lewis et al. · 0 citations
Open access Sep 2026

Impact of ATP8B1 Mutation and Maturation on CFTR Functionality and Gene Expression

A physical association between ATP8B1 and CFTR is revealed, supporting a chaperone role for ATP8B1 in CFTR trafficking and membrane insertion and providing new insights into the molecular link between PFIC1 and cystic fibrosis-associated liver disease.

J. Sergent, C. Hulen, N. Lomri · 0 citations
Sep 2026

CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.

BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only FDA-approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treat...

Ying-Shu Cao, Xiao-Bo Sun, Yan Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.